Amgen Inc.

Tularik Limited

Japan Tobacco Inc.

Ptc Therapeutics, Inc.

Other

Tularix Inc.

Steven Marc Rubenstein

Lawrence R McGee

Jonathan B Houze

Juan Carlos Jaen

Noboru Furukawa

Hisashi Shinkai

Atsushi Hagiwara

Neil Gregory Almstead

John A Flygare

Ellen Welch

Timothy David Cushing

James Jan Takasugi

Richard Gerald Wilde

Jin-Long Chen

Patrick C Kearney

Holger Beckmann

Shi-Chang Miao

Fabienne De La Brouse-Elwood

Masahiro Tanaka

Frank Kayser

Takashi Inaba

Dustin L McMinn

Xiaolin Hao

Marc Labelle

Brian M Fox

Kexue Li

Simon Mark Jackson

Jian Zhang

Atsuhito Yoshida

Shoichi Sagawa

Kiyosei Iio

Kazuyuki Sugimoto

Takuya Matsui

Nobuya Ogawa

Masahiro Suzuki

Guosen Ye

Modulators of PPAR&#x3b3; activity are provided which are useful in pharmaceutical compositions and methods for the treatment of conditions such as type II diabetes and obesity.

Compounds for the modulation of PPAR&#x3b3; activity

Compounds, compositions and methods are provided that are useful in the treatment or prevention of a condition or disorder mediated by PPAR&#x3b3;. In particular, the compounds of the invention modulate the function of PPAR&#x3b3;. The subject methods are particularly useful in the treatment and/or prevention of diabetes, obesity, hypercholesterolemia, rheumatoid arthritis and atherosclerosis.

Quinolinyl and benzothiazolyl modulators

Novel acetylamino benzoic acid compounds, methods of using and pharmaceutical compositions comprising an acetylamino benzoic acid derivative are disclosed. The methods include methods of treating or preventing a disease ameliorated by modulation of premature translation termination or nonsense-mediated mRNA decay, or ameliorating one or more symptoms associated therewith.

Use of Acetylamino benzoic acid compounds for nonsense suppression and the treatment of disease

PPAR&#x3b3; modulators

Acetylamino benzoic acid compounds and their use for nonsense suppression and the treatment of disease

Compounds, pharmaceutical compositions and methods that are useful in the treatment or prevention of metabolic and cell proliferative diseases or conditions are provided herein. In particular, the invention provides compounds which modulate the activity of proteins involved in lipid metabolism and cell proliferation.

Fused bicyclic nitrogen-containing heterocycles

Modulators of PPAR&ggr; activity are provided which are useful in pharmaceutical compositions and methods for the treatment of conditions such as type II diabetes and obesity.

Compounds for the modulation of PPAR&ggr; activity

The invention provides compounds, compositions and methods relating to novel arylsulfonanilide derivatives and their use as pharmacologically active agents. The compositions find particular use as pharmacological agents in the treatment of disease states, particularly cancer, psoriasis, vascular restenosis, infections, atherosclerosis and hypercholesterolemia, or as lead compounds for the development of such agents.

Arylsulfonanilide derivates

PPAR&ggr; modulators

Compounds, compositions and methods are provided that are useful in the treatment or prevention of a condition or disorder mediated by PAPAR&ggr;. In particular, the compounds of the invention modulate the function of PAPAR&ggr;. The subject methods are particularly useful in the treatment and/or prevention of diabetes, obesity, hypercholesterolemia, rheumatoid arthritis and atherosclerosis.

PPAR-&ggr; modulators

Arylsulfonanilide derivatives

Growing community of inventors

Pacifica, CA, United States of America

Steven Marc Rubenstein